| INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Patent applications |
| Patent application number | Title | Published |
|---|
| 20120115171 | Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S. | 05-10-2012 |
| 20120100124 | METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER - The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | 04-26-2012 |
| 20120093795 | COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR - The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies. | 04-19-2012 |
| 20120093725 | Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies - The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis. | 04-19-2012 |
| 20120088259 | Post-Translation Modified Cardiac Troponin T As A Biomarker Of A Risk For Heart Failure - The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker. | 04-12-2012 |
| 20120064094 | Serotonin 5-HT3 Receptor Antagonists for Use in the Treatment of Lesional Vestibular Disorders - The invention relates to serotonin 5-HT3 receptor antagonists or inhibitors of serotonin 5-HT3 receptor gene expression for use in the treatment of a lesional vestibular disorder. | 03-15-2012 |
| 20120058110 | Method for Predicting the Responsiveness to an Anti-TNF Alpha Antibody Treatment - The present invention relates to a method for predicting the responsiveness of a patient to an anti-TNFα antibody treatment. | 03-08-2012 |
| 20120046181 | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status - The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and/or monitoring of treatment regimens. | 02-23-2012 |
| 20120015387 | MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT - An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa. | 01-19-2012 |
| 20120003224 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 01-05-2012 |
| 20110256559 | Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta - The present invention relates to a method for detection or quantification of sAPPα and/or sAPPβ in a sample and their use for diagnosing and/or monitoring a neurodegenerative disease in a subject in need thereof and kit for use in said method. | 10-20-2011 |
| 20110244459 | METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS - Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library. | 10-06-2011 |
| 20110236347 | Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection - The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described. | 09-29-2011 |
| 20110218232 | Inhibitors of MRP4 and Agents Stimulating MRP4 Activity for the Treatment of Cardiac Disorders - The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy. | 09-08-2011 |
| 20110212098 | Novel Melanoma Antigen Peptide and Uses Thereof - The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma. | 09-01-2011 |
| 20110185441 | TRANSGENIC ANIMALS AND METHODS OF MAKING RECOMBINANT ANTIBODIES - The present invention describes a means for obtaining cells which produce human, humanized or chimeric antibodies in commercially useful quantities. The invention permits high antibody producer cells to be selected and isolated from animals for use in culture to produce antibodies. The invention also provides methods for the affinity maturation of human, humanized or chimeric immunoglobulins. | 07-28-2011 |
| 20110177970 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 07-21-2011 |
| 20110166428 | NOVEL METHOD FOR MEASURING INSULIN RESISTANCE - Method of using at least one glucose derivative, halogenated in the 6 position, for the implementation of a process for the determination of insulin resistance in a mammal, in particular man, by measuring
| 07-07-2011 |
| 20110135661 | TREATMENT AND PREVENTION OF DRY AGE-RELATED MACULAR DEGENERATION BY ACTIVATING CD36 - The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36-activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1 [A-(Xaa) | 06-09-2011 |
| 20110104136 | Natural Killer p30 (NKp30) Dysfunction and the Biological Applications Thereof - The present invention relates to a method of assessing a favourable or, on the contrary, an unfavourable prognosis of a cancer in the subject, which method comprises detecting the presence of a mutated Natural Cytotoxicity-triggering Receptor 3 (NCR3) nucleic acid, an abnormal relative amount of at least one particular Natural Killer p30 (NKp30) RNA transcript isoform, and/or an abnormal Natural Killer p30 (NKp30) expression or activity of at least one particular NKp30 protein isoform in a sample from the subject, the presence of said mutated NCR3 nucleic acid, abnormal relative amount of at least one particular NKp30 RNA transcript isoform, or abnormal expression or activity of at least one particular NKp30 protein isoform being indicative of the prognosis of said cancer in the subject. | 05-05-2011 |
| 20110070242 | Methods for Diagnosing and Treating Iron Dysregulation - The present invention relates to methods for diagnosing and treating iron overload and iron deficiency. | 03-24-2011 |
| 20110070238 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 | 03-24-2011 |
| 20110065609 | Methods and Kits for the Diagnosis of Rheumatoid Arthritis - The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens. | 03-17-2011 |
| 20110044906 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 02-24-2011 |
| 20110028838 | Method and Apparatus for Measuring a Physical Parameter in Mammal Soft Tissues by Propagating Shear Waves - Method for measuring a physical parameter in soft tissues of a mammal, in which a mechanical shear wave is propagated through the soft tissues and observation of the propagation leads to determine values of a shear wave propagation parameter. The physical parameter is computed on the basis of these values. | 02-03-2011 |
| 20100316616 | Use of FZC18-Containing Collagen 18 Polypeptides for the Treatment, Diagnosis and Outcome Prediction of Diseases - The present invention relates to a polypeptide comprising at least 13 consecutive amino acids selected from the amino acid sequence as set forth in SEQ ID NO: 1 or a variant thereof comprising at least 70% identity over said 13 consecutive amino acids, wherein said polypeptide or variant thereof interacts with Wnt3a and can be used for the treatment of diseases associated with increased beta-catenin pathway activity. The present invention also relates to a method for detecting the presence of a disease associated with fibrogenesis and to a method for assessing the severity and/or predicting the outcome of cancer. | 12-16-2010 |
| 20100303828 | Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity - The invention relates to antibodies against human CD39 and use thereof for inhibiting T regulatory cells (Treg) activity. More particularly CD39 antibodies may be used for the treatment or prevention of cancers and infectious diseases. | 12-02-2010 |
| 20100284991 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases - The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis). | 11-11-2010 |
| 20100278809 | Inhibitors of MRP4 for the Treatment of Vascular Disorders - The invention relates to inhibitors of MRP4 for the treatment and/or the prevention of vascular disorders such as atherosclerosis, post-angioplasty restenosis, pulmonary arterial hypertension or vein-graft disease. | 11-04-2010 |
| 20100261654 | COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION - Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject. | 10-14-2010 |
| 20100210566 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS - An azapeptide derivative of growth hormone releasing peptide (GHRP) of Formula I: A-(Xaa) | 08-19-2010 |
| 20100203575 | In Vitro Beating Heart Model - The invention relates to a method for preparing a heart organotypic slice culture, comprising; a) providing a slice of heart, b) placing the slice of step a) on the upper surface of a semiporous support which is permeable to a culture medium, c) placing the support of step b) onto a culture medium, the slice being fed through the semi-porous support by capillarity. | 08-12-2010 |
| 20100196921 | Method for Predicting the Outcome of a Critically Ill Patient - The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient. | 08-05-2010 |
| 20100196386 | LIGANDS OF HVEM FOR TREATING HEMATOLOGIC MALIGNANCIES AND AUTOIMMUNE DISEASES - The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases. | 08-05-2010 |
| 20100184707 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation. | 07-22-2010 |
| 20100124555 | Compositions and Methods for Treating Pancreatic Tumors - The present invention relates to a method for producing an antigen-binding compound suitable for use in the treatment of cancer, the antigen-binding compounds and their uses. | 05-20-2010 |
| 20100113933 | CHIRP REVERSAL ULTRASOUND CONTRAST IMAGING - The invention relates to a method for detecting and imaging ultrasound echo signals returned from a target object comprising microbubbles, said microbubbles being characterized by a resonance frequency, said method comprising the steps of irradiating said target object with at least a first and second successive excitation signals, said first excitation signal being a sweep of increasing frequency with time, and said second excitation signal being a sweep of decreasing frequency with time, detecting echo signals of said first and second excitation signals from said target object, and, combining said echo signals. The maximum frequencies of said first and second excitation signals are lower than said resonance frequency. The invention also relates to an imaging apparatus. | 05-06-2010 |
| 20100112605 | Biomarker for the Medicine and the Biology of the Reproduction - The present invention relates to a new biomarker for the medicine and the biology of reproduction, in particular for in vitro fertilization (IVF) outcome. It relates to methods for predicting IVF outcome and for selecting the subject for IVF. | 05-06-2010 |
| 20100104581 | Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions - The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described. | 04-29-2010 |
| 20100063147 | Anaplerotic Therapy of Huntington Disease and Other Polyglutamine Diseases - The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof. | 03-11-2010 |
| 20100062987 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance. | 03-11-2010 |
| 20100022504 | METHODS FOR TREATING LATENT TUBERCULOSIS - A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals. | 01-28-2010 |
| 20100015653 | Compounds Regulating Calreticulin, KDEL Receptor and/or ERP-57 Cell Surface Exposure and Uses Thereof to Evaluate the Efficiency of a Cancer Treatment - The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell. | 01-21-2010 |
| 20100008932 | USE OF SOLUBLE CD160 TO SUPPRESS IMMUNITY - Pharmaceutical composition including a soluble form of CD160 for treating an inflammatory condition involving an undesired immune response, such as tissue graft or organ rejection, and autoimmune diseases; in vitro method for screening an individual for the presence of an inflammatory condition such as infectious and autoimmune diseases, tissue graft and organ rejection, or the presence of a tumor or activated endothelial cells, or for monitoring therapy of an inflammatory condition such as an autoimmune disorder or a tissue or organ rejection, or a tumor during chemotherapy including treatment with an anti-angiogenic substance or antibody. | 01-14-2010 |
| 20100003272 | Method for Expanding Monocytes - The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signaling. | 01-07-2010 |
| 20090318540 | NUCLEIC ACIDS FOR EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN MAMMALIAN CANCER CELLS - The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells. | 12-24-2009 |
| 20090311714 | Methods for the Screening of Antibacterial Substances - The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof. | 12-17-2009 |
| 20090305343 | Method For Expressing Polypeptides In Eukaryotic Cells Using Alternative Splicing - This invention relates to an expression cassette for expressing polypeptides in eukaryotic cells using alternative splicing. The expression cassette comprises in 5′ to 3′ downstream direction: a promoter; a sequence transcribed in a 5′ untranslated region (5′UTR); a donor splice site; an intron; a first acceptor splice site; a first cistron encoding a first polypeptide; a second acceptor splice site; a second cistron encoding a second polypeptide; an internal ribosome entry site (IRES) operably linked to a selection marker; and a sequence transcribed in a 3″ untranslated region (3′UTR) including a polyadenylation signal, wherein the polyadenylation signal is unique. | 12-10-2009 |
| 20090286689 | METHODS FOR ANALYZING DIFFERENTIAL GENE EXPRESSION ASSOCIATED WITH MYELOPROLIFERATIVE DISORDERS (MPD) CANCER DISEASE - The present application relates to gene analysis and, in particular, to gene expression profiling for identifying molecular signature of cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer and studying cancer. | 11-19-2009 |
| 20090281461 | DEVICE AND METHOD FOR THE TIME-BASED ANALYSIS OF THE AGITATION OF A BEDRIDDEN PATIENT - Device for the time-based analysis of the agitation of a bedridden patient includes elements ( | 11-12-2009 |
| 20090252740 | Method for Predicting Responsiveness to TNF Alpha Blocking Agents - The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNFα blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method. | 10-08-2009 |
| 20090215053 | Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method - The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer. | 08-27-2009 |
| 20090175892 | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 07-09-2009 |
| 20090131378 | VITAMIN D DERIVATIVES ACTIVE ON THE VITAMIN D NUCLEAR RECEPTOR, PREPARATION AND USES THEREOF - The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy and osteoporosis. It further relates to pharmaceutical compositions comprising said compounds and methods for preparing the same. | 05-21-2009 |
| 20080280318 | Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof - The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells. | 11-13-2008 |
| 20080255039 | Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity - The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor α-chain. Two IL-15 regions are involved in the formation of this epitope: the first region ( | 10-16-2008 |
